Brief: Index Pharmaceuticals Prepares For Commercialisation Of Cobitolimod

Flerie AB

13/03/2022 20:29

March 13 (Reuters) - 
    * INDEX PHARMACEUTICALS PREPARES FOR COMMERCIALISATION OF
COBITOLIMOD
    * INDEX PHARMACEUTICALS HOLDING AB - LAUNCH IS EXPECTED IN
2027,
WITH POTENTIAL FOR ANNUAL SALES TO REACH MORE THAN USD 1
BILLION, IN MODERATE TO SEVERE LEFT-SIDED ULCERATIVE COLITIS
    * INDEX PHARMACEUTICALS HOLDING AB - RESULTS FROM ONGOING
FIRST
PHASE III STUDY WITH COBITOLIMOD ARE EXPECTED TO BE AVAILABLE
DURING H2 2023
    * INDEX PHARMACEUTICALS HOLDING AB -  PHASE III PROGRAM,
INCLUDING
A SECOND INDUCTION STUDY, ONE-YEAR MAINTENANCE STUDY, EXPECTED
TO BE COMPLETED IN 2026

Source text for Eikon:  ID:nWkr80vjmR 
Further company coverage: [ ]

 ((Reuters.Briefs@thomsonreuters.com;))